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A surface marker that distinctly identifies cardiac
progenitors (CPs) is essential for the robust isolation
of these cells, circumventing the necessity of genetic
modification. Here, we demonstrate that a Glyco-
sylphosphatidylinositol-anchor containing neurotro-
phic factor receptor, Glial cell line-derived neurotro-
phic factor receptor alpha 2 (Gfra2), specifically
marks CPs. GFRA2 expression facilitates the isola-
tion of CPs by fluorescence activated cell sorting
from differentiating mouse and human pluripotent
stem cells. Gfra2 mutants reveal an important role
for GFRA2 in cardiomyocyte differentiation and
development both in vitro and in vivo. Mechanis-
tically, the cardiac GFRA2 signaling pathway is
distinct from the canonical pathway dependent on
the RET tyrosine kinase and its established ligands.
Collectively, our findings establish a platform for
investigating the biology of CPs as a foundation for
future development of CP transplantation for treating
heart failure.
INTRODUCTION
The heart is the first morphologically distinct developing organ in
vertebrates. The primordial heart is derived from the anterior part
of the lateral plate mesoderm as cardiac progenitors (CPs) being
one of the earliest populations emerging from the primitive streak1026 Cell Reports 16, 1026–1038, July 26, 2016 ª 2016 The Author(s
This is an open access article under the CC BY license (http://creativeat gastrulation (Kinder et al., 1999; Rana et al., 2013). Lineage
tracing experiments have led to the identification of CPs in the
first (FHF) and second heart field (SHF) according to their
anatomical origin and destiny (Rana et al., 2013). Recently,
studies have delineated the complex molecular mechanisms
underlying cardiomyocyte differentiation (Kathiriya et al., 2015;
Paige et al., 2015); however, our knowledge of the precise
spatiotemporal mechanisms that regulate the segregation, iden-
tity, and fate of CPs remains incomplete. A major hurdle is the
paucity of reliable and specific markers to identify CPs, espe-
cially for the robust isolation of living CPs using cell sorting, cir-
cumventing the requirement of genetic modification for tagging
CPs. Previous reports have demonstrated that Kinase insert
domain receptor (KDR, also known as Flk-1), platelet-derived
growth factor receptor alpha (PDGFRA), KIT, C-X-C chemokine
receptor type 4 (CXCR4), and/or Prion protein (PrnP) can be
used in defined combinations to identify and harvest CPs (Bon-
due et al., 2011; Hidaka et al., 2010; Kattman et al., 2006, 2011;
Nelson et al., 2008; Yang et al., 2008). In vitro clonal-tracing
studies have revealed that both KDR+/PDGFRA+ and KDRlow+/
KITneg cell populations contain highly enriched multipotent pro-
genitors producing not only cardiomyocytes but also endothelial
and smooth muscle cells in mouse and human, respectively
(Kattman et al., 2006, 2011; Yang et al., 2008). Moreover, since
the expression pattern of each of these factors in the embryo
is dynamic and not specific for the cardiac lineage (Hidaka
et al., 2010; Kataoka et al., 1997; McGrath et al., 1999; Yang
et al., 2008), concerns have been raised about the purity of
CPs harvested using these markers. More recently, a cell-
surface protein, hyperpolarization-activated cyclic nucleotide-
gated potassium channel 4 (HCN4), has been reported to be).
commons.org/licenses/by/4.0/).
transiently specific for FHF CPs during the earliest phase of car-
diomyogenesis (Spa¨ter et al., 2013). However, because there is
no commercially available antibody against the extracellular
domain of this molecule, its use in cell-sorting experiments
is limited. Thus, identification of a CP-specific surface antigen
for which an antibody is readily available is essential for
furthering our understanding of the critical early events in heart
development.
In this study, we found that Glial cell line-derived neurotro-
phic factor receptor alpha 2 (Gfra2) specifically marks CPs
of the FHF and SHF in mouse and human (Airaksinen and
Saarma, 2002; Paratcha and Ledda, 2008). The specificity
and expression pattern of Gfra2 provides a reliable means to
isolate stage-specific CPs with high purity. Strikingly, Gfra2 is
essential for heart development, whereas Gfra1, another mem-
ber of the Gfra receptor family, is functionally redundant.
Finally, we demonstrate that the pathway by which GFRA1/2
modulates heart development is independent of the classical
Gfra receptor family signaling pathway via the RET proto-
oncogene.
RESULTS
Gfra2 Specifically Marks Both FHF and SHF CPs
According to previous single-cell expression profiling of mouse
embryonic CPs between days 7.5 and 8.0 post-conception
(E7.5–E8.0), we observed that Gfra2, a specific receptor for
a neurotrophic factor Neurturin (NRTN), was expressed in
CPs but not in embryonic stem cells (ESCs) (42.31 ± 22.53
SEM of CPs versus 0.00 of ESCs in Reads Per Millions,
respectively) (Brouilette et al., 2012; Kokkinopoulos et al.,
2015). This was consistent with the data demonstrating that
Gfra2 was co-expressed within the cardiac mesoderm ex-
pressing Mesp1 (Bondue et al., 2011). To confirm the expres-
sion pattern of Gfra2 in mouse embryos, we conducted whole-
mount in situ hybridization (WISH) analyses in serial stages
of early mouse embryos and found that Gfra2 was detected
from the Early Allantoic Bud stage simultaneously with one
of the earliest markers of CPs, Isl1, and was clearly expressed
in the cardiac crescent from E7.5 to E8.5 (Figures 1A and
S1A) (Downs and Davies, 1993; Kokkinopoulos et al., 2015).
Single-cell expression profiling suggests that Isl1 precedes
Gfra2, because Isl1-expressing CPs had a higher incidence
of expression of Gfra2 after they had started to express a
common marker for the FHF and SHF, Nkx2-5, as they further
differentiated (Figure S1B) (Kokkinopoulos et al., 2015). There-
after, Gfra2 was downregulated in the heart field by the ten-
somite stage (E8.75) upon formation of the heart tube (Fig-
ure 1A). Immunofluorescence micrographs indicated that
GFRA2 protein was prominently detected in the early headfold
(EHF) stage CPs (Figure 1B) (Downs and Davies, 1993). Serial
sections of the three-somite stage embryos revealed that
GFRA2 co-localized with NKX2-5, TBX5, HCN4 (the FHF),
and ISL1 (the SHF) (Figures 1C and S1C) (Cai et al., 2003; De-
vine et al., 2014; Kokkinopoulos et al., 2015; Liang et al., 2013;
Spa¨ter et al., 2013; Stanley et al., 2002). Therefore, GFRA2 can
be considered a marker of CPs within both the FHF and SHF in
mouse embryos.GFRA2 Predominantly Identifies CPs Derived from
Pluripotent Stem Cells
Next, to clarify whether GFRA2 marks CPs derived from pluripo-
tent stem cells, we investigated the expression of Gfra2 during
cardiac differentiation of mouse ESCs. Quantitative real-time
reverse transcription PCR (qPCR) demonstrated that Gfra2
was transiently expressed with its peak at differentiation day 7,
before the initiation of spontaneous beating of differentiated
cardiomyocytes (Figure 2A). Flow cytometry using an antibody
raised against the extracellular domain of GFRA2 revealed that
GFRA2 could be identified between differentiation days 4–9,
among the PDGFRA positive mesodermal cells (Figures 2B
and S2A). Upon culturing the separately isolated cell populations
of GFRA2+/PDGFRA+, GFRA2neg/PDGFRA+, and GFRA2neg/
PDGFRAneg at differentiation day 7 by fluorescent activated
cell sorting (FACS), the majority of GFRA2+/PDGFRA+ cells
differentiated into TNNT2+ and ACTN1 (a-ACTININ)+ cardiomyo-
cytes, without a propensity for differentiation to endothelial cells
and smooth muscle cells (Figures 2C–2F, S2B, and S2C; Movie
S1). By contrast, the other cell populations rarely contained such
cardiac cells. These results suggest that GFRA2+/PDGFRA+
cells at day 7 are already committed to a cardiomyocyte fate
but remain as precursor cells without terminal differentiation.
The expression of NKX2-5 (common), TBX5 (FHF), HCN4
(FHF), and ISL1 (SHF) in GFRA2+/PDGFRA+ cells demonstrated
that GFRA2+/PDGFRA+ CPs reside in both the FHF and SHF
(Figures 2G and S2D) (Cai et al., 2003; Devine et al., 2014; Kok-
kinopoulos et al., 2015; Liang et al., 2013; Spa¨ter et al., 2013;
Stanley et al., 2002). These data were consistent with our histo-
logical results in mouse embryos (Figures 1C and S1C).
To further characterize GFRA2+ cells during cardiac differenti-
ation, we investigated the relationship between GFRA2-ex-
pressing CPs and the well-validated earliest CPs of the KDR+/
PDGFRA+ population in differentiating mouse ESCs (Kattman
et al., 2006, 2011). KDR and PDGFRA were already expressed
by day 3 of differentiation as previously described (Kattman
et al., 2011), and KDR expression was downregulated in the
PDGFRA+ population at day 6 (Figure 3A). Of note, from day 4
to 5, almost the entire KDR+/PDGFRA+ population expressed
GFRA2. Thus, GFRA2 could also mark the earliest mouse CPs
in cardiac differentiating ESCs. When we isolated a GFRA2+/
KDR+/PDGFRA+ triple-positive population on day 4 and cultured
the cells for a further 7 days, they gave rise not only to cardiomyo-
cytes, but also to endothelial cells (Figure 3B). Given that GFRA2
markedKDR+/PDGFRA+CPs on differentiation day 4, the earliest
GFRA2+CPswould be expected to bemultipotent based on pre-
vious reports (Bondue et al., 2011; Kattman et al., 2011). There-
after, KDRexpressionwould be limited to the endothelial lineage,
with cardiomyogenic cells having lost KDRexpression after day 6
of differentiation (Figures 3A, S2E, and S2F). Taken together, our
findings clearly demonstrate that GFRA2 facilitates the robust
isolation of CPs from differentiating mouse ESCs.
GFRA2 Marks Human CPs from Differentiating Human
Pluripotent Stem Cells
To challengewhether humanGFRA2 can be used forCP isolation
from human pluripotent stem cells, we investigated the expres-
sion of humanGFRA2 during the cardiac differentiation of humanCell Reports 16, 1026–1038, July 26, 2016 1027
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Figure 1. GFRA2 Is Expressed in the First and Second Heart Field Cardiac Progenitor Cells
(A) Whole-mount in situ hybridization (WISH) ofGfra2 in E7.25–8.75 early allantoic bud (EB) stage to the ten-somite (S) stage embryos.Gfra2was expressed in the
cardiac crescent (arrows). Once the heart tube is formed and the looping initiated, Gfra2 is downregulated (red arrowheads). Gfra2 was also expressed in
migrating neural crest cells and the rhombomere 4 (white arrowheads). n = 3. Scale bar, 250 mm. EHF, early headfold; LHF, late headfold.
(B and C) Immunohistochemical (IHC) images of GFRA2 in an EHF and three-somite stage embryo. GFRA2 was expressed in the mesodermal regions corre-
sponding to the heart field. n = 4. Scale bar, 50 mm. FHF, first heart field; SHF, second heart field.
See also Figure S1.
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Figure 2. GFRA2+/PDGFRA+ Cells Derived from Mouse ESCs Are Unipotent Cardiac Precursors
(A) qPCR analyses ofGfra2,Mesp1, T (Brachyury), Nkx2-5, Tbx5, andMyl2. The peak ofGfra2 expression was observed just before the initiation of spontaneous
beating of cardiomyocytes. Note that mesodermal induction represented byMesp1 and T peaked at day 3 and sarcomeric protein synthesis of cardiomyocyte
was apparent from day 8. Data are representative of biological triplicates with technical duplicates as mean ± SEM.
(B) Flow cytometrical (Flo) analyses show transient expression of GFRA2 during cardiomyocyte differentiation. GFRA2 was detected in the PDGFRA+ meso-
dermal population from day 4 to day 9.
(C) FACS isolation at day 7 of differentiation. GFRA2+/PDGFRA+ (G+P+), GFRA2/PDGFRA+ (GP+), GFRA2/PDGFRA (GP) populations were separately
isolated.
(D) Immunocytochemistry (ICC) of TNNT2 in FACS-isolated cells after an additional 5 days culture in differentiation media. The condensed high DAPI signals
represent dead cells. We counterstained with TUBA1A (a-tubulin) to delineate the live cells and found that most of G+P+ cells differentiated into TNNT2+
cardiomyocytes. Scale bar, 100 mm.
(E and F) Flow cytometrical (Flo) analyses for TNNT2 revealed that most of the G+P+ cells (93.6% ± 3.1%) differentiated into cardiomyocytes. n = 3.
(G) Quantitative analyses by Flo for HCN4, NKX2-5, TBX5, and ISL1 in GFRA2+ CPs at day 7. Bar graph represents of the proportion of FHF and SHF as
mean ± SEM. n = 3.
See also Figure S2 and Movie S1.
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Figure 3. GFRA2+/KDR+/PDGFRA+ Repre-
sents Multipotent CPs
(A) Flo analyses for KDR, PDGFRA, and GFRA2.
KDR+/PDGFRA+ cells were observed at day 3, but
these were GFRA2 negative. After day 4, most of
KDR+/PDGFRA+ CPs were GFRA2 positive (Katt-
man et al., 2011). KDR expression was significantly
downregulated at day 6.
(B) FACS isolation of GFRA2+/KDR+/PDGFRA+
population at differentiation day 4. Immunocyto-
chemical and flow cytometrical analyses for TNNT2,
PECAM1, and ACTA2 (a- smooth muscle cell
actin) reveal that this population differentiated into
both cardiomyocytes and endothelial cells. This is
consistent with the previous study (Kattman et al.,
2011), which shows this population is multipotent
cardiovascular progenitors. Scale bar, 100 mm.
See also Figure S2.ESCs or induced pluripotent stem cells (iPSCs) (Burridge et al.,
2011). Consistent with our results for the mouse, qPCR analyses
showed human GFRA2 was induced with a peak just before the
appearance of spontaneously beating cardiomyocytes at day 8
of differentiation, both in ESCs and iPSCs (Figures 4A and
S3A).We also identified the hGFRA2+/hPDGFRA+ cell population
at day 8 by flow cytometry, with FACS-isolated hGFRA2+/
hPDGFRA+ cells efficiently differentiating into TNNT2+ cardio-
myocytes when cultured for an additional 5 days (Figures 4B–
4D and S3B–S3D). These TNNT2+ cardiomyocytes demon-
strated spontaneous beating (Movie S2). The expression profiles
of FACS-purified hGFRA2+/hPDGFRA+ cells suggest that this
population contains both the FHF and SHF CPs, similarly as in
thecaseofmouseESCs (Figures 2G,4E, andS2D). Thus, labeling
with antibodies raised to humanGFRA2alsoenables the isolation
of aCPpopulation fromhumanpluripotent stemcells,without the
need of lineage tagging by genetic modification.
To elucidate additional details concerning the earliest phase of
hGFRA2+ CPs in human cardiac differentiation, we performed
flow cytometry using hGFRA2, hPDGFRA, hKDR, and hKIT anti-1030 Cell Reports 16, 1026–1038, July 26, 2016bodies at day 4 of differentiation. We found
that the proportion of hGFRA2-expressing
cells among the multipotent CP-enriched
population of hKDRlow+/hPDGFRA+ cells
were less than in the case of mouse
(Figures 3A and 4F) (Kattman et al., 2011).
As expected, the hKDRlow+/hPDGFRA+
population was hKIT negative, whereas
hKDR+/hPDGFRAneg population was hKIT
positive (Figure 4F) (Yang et al., 2008). By
separating isolated hGFRA2+/hKDRlow+/
hPDGFRA+/hKITneg and hGFRA2neg/
hKDRlow+/hPDGFRA+/hKITneg populations,
we found that the GFRA2 negative pop-
ulation almost lacked cardiomyogenic
ability (FigureS3E). Toconfirmmultipotency
of human GFRA2 positive cells, we per-
formed clonal lineage-tracing experiments.
A single hGFRA2+/hKDRlow+/hPDGFRA+/hKITneg cell at day 4 was cloned by FACS and cultured for
2 weeks. RT-PCR using cardiomyocyte (hTNNT2), endothelial
cell (hPECAM), and smoothmuscle cell (hMYH11) markers clearly
indicated the existence of themultiple cell lineages derived from a
single cell, which strongly supports themultipotency of hGFRA2+/
hKDRlow+/hPDGFRA+/hKITneg cells (Figure 4G). This is consistent
with the data from mouse ESCs and previous work (Kattman
et al., 2006, 2011; Yang et al., 2008). After differentiation day 4,
as cardiomyocyte differentiation progressed, GFRA2+/PDGFRA+
CPs lost KDR expression by day 8 as observed in mouse ESCs
differentiation (Figure S3F). Taken together, as in the mouse,
hGFRA2+/hKDRlow+/hPDGFRA+/hKITnegCPsatday4aremultipo-
tent CPs, and hGFRA2+/hKDRneg/hPDGFRA+/hKITneg at day 8 are
unipotent cardiac precursors.
A Non-canonical Signaling Cascade via GFRA1/2 Is
Indispensable for Cardiomyocyte Differentiation of
Pluripotent Stem Cells
To elucidate a physiological function of GFRA2 in cardiac differ-
entiation, we generated Gfra2 knockout (KO) mouse ESC lines
A B
C D E
F G
Figure 4. Human GFRA2 Marks CPs from
Human ESC Cultures
(A) qPCR analyses for human GFRA2, NKX2-5,
TBX5, and MYL2. Note the peak of human GFRA2
expression is just before human embryoid bodies
start to beat. Bar graph represents biological tripli-
cates with technical duplicates as mean ± SEM.
(B) FACS isolation of human hGFRA2+/hPDGFRA+
(G+P+) cells. ICC analyses for TNNT2 demonstrate
that isolated G+P+ population is highly cardiomyo-
genic. Scale bar, 100 mm.
(C and D) Quantitative analyses by Flo for TNNT2
show most of G+P+ cells (96.5% ± 1.1%) differenti-
ated into cardiomyocytes. Bar graph represents
mean ± SEM. n = 3.
(E) qPCR analyses for GFRA2, NKX2-5, ISL1, TBX5,
and HCN4 in FACS-isolated populations. All cardiac
marker gene expressions were significantly higher in
the G+P+ population when compared to the GP
population (*p < 0.05, Student’s t test). Data are
representative of biological triplicates with technical
duplicates as mean ± SEM.
(F) Flow cytometry of human ESCs at differentiation
day 4. hGFRA2+ cells (shown as green dots) were
mostly included by hPDGFRA+/hKDRlow+/hKITneg
population, which is reported as multipotent CPs
(Yang et al., 2008). 15%–20% of hPDGFRA+/
hKDRlow+/hKITneg cells were hGFRA2+.
(G) RT-PCR analyses of single-cell-derived colonies
for each lineage marker gene. A single hGFRA2+/
hKDRlow+/hPDGFRA+ cell at day 4 was clonally
sorted and cultured on mouse embry-
onic fibroblasts (MEFs) for 2 weeks. RT-PCR of
hTNNT2, hPECAM1, and hMYH11 represent the
existence of cardiomyocytes, endothelial cells, and
smooth muscle cells among the cells derived from a
single cell, respectively. Note the existence
of multiple lineages, which indicates the multi-
potency.
See also Figure S3 and Movie S2.using the CRISPR/Cas9 genome editing system (Figures 5 and
S4) (Cong et al., 2013;Wang et al., 2013). After 10 days of cardiac
differentiation, two independent lines of Gfra2-KO ESCs did
not show significant defects in cardiomyocyte differentiation,
although a minor decrease in the number of differentiated cardi-
omyocytes was observed without statistical significance (Fig-
ures 5A–5C). This is consistent with the phenotype of KO mice
that showed no cardiac defects (Airaksinen and Saarma, 2002;
Hiltunen et al., 2000; Paratcha and Ledda, 2008; Rossi et al.,
1999, 2003). Since GFRA1, another member of GFRA-family
receptor whose specific ligand is glial cell line-derived neurotro-
phic factor (GDNF), might be functionally redundant, we gener-
ated compound mutant of Gfra1/2 double-KO (DKO) ESCs (Air-
aksinen and Saarma, 2002; Baloh et al., 2000). Whereas Gfra1
KO lines exhibited no significant defect in cardiomyocyte differ-
entiation (Enomoto et al., 1998), the simultaneous ablation of
Gfra1 in addition to Gfra2 significantly suppressed cardiomyo-
cyte differentiation (Figures 5A–5C and S4A–S4E). It is unlikely
that an off-target mutation is responsible for this phenotype,because two independent single guidance (sg) RNA targeting
different portions of the gene resulted in an indistinguishable
phenotype (Figures S4C and S4D) (Enomoto et al., 1998; Fu
et al., 2013; Hiltunen et al., 2000; Rossi et al., 1999, 2003).
Thus, Gfra1/2 are required for cardiomyocyte differentiation
in vitro, and Gfra1 is functionally redundant for Gfra2. Interest-
ingly, we found thatGfra1 expression was significantly increased
inGfra2KO ESCs (Figure 5D). By contrast,Gfra2 expression was
unchanged in Gfra1 KO ESCs. This result suggests that the loss
ofGfra2 can be compensated for by upregulatedGfra1, whereas
Gfra1 appears to be dispensable for cardiac differentiation (Ba-
loh et al., 2000; Paratcha and Ledda, 2008; Scott and Ibanez,
2001). This suggestion is supported by the fact that Gfra1 is
not expressed in the heart field in vivo (Figure S5A).
The canonical signaling cascade acting via GFRA2 depends
on a single-pass transmembrane protein, RET tyrosine kinase
(Airaksinen and Saarma, 2002). When the specific ligand, neu-
rturin (NRTN) binds GFRA2, the RET tyrosine kinase is activated
by GFRA2/NRTN, to elicit a biological response. To confirmCell Reports 16, 1026–1038, July 26, 2016 1031
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Figure 5. Gfra1 and Gfra2 Are Essential for
In Vitro Cardiomyocyte Differentiation from
Mouse ESCs
(A) Flo analyses of TNNT2 at day 10 of differentia-
tion. WT, wild-type; G1-KO, Gfra1-KO; G2-KO,
Gfra2-KO; DKO, Gfra1/2-DKO; R-KO, Ret-KO; ISO
CTRL, isotype control.
(B) Quantitative analyses of flow cytometry show the
severe impairment of cardiomyocyte differentiation
in Gfra1/2 DKO ESC lines. *p < 0.05 versus WT in
Student’s t test. n = 5.
(C) Immunocytochemical analyses of each KO ESC
line 10 days after induction of cardiomyocyte dif-
ferentiation. Gfra1/2 double-KO (DKO) ESCs ex-
hibited severe defects in TNNT2+ cardiomyocyte
differentiation. Scale bar, 100 mm.
(D) qPCR analyses for Gfra1 and Gfra2 in Gfra2 KO
ESC lines and in Gfra1 KO ESC line at day 7,
respectively. Note the elevated expression of Gfra1
in Gfra2 KO ESCs. *p < 0.05 versus WT in Student’s
t test. N.S., not significant. Bar graph represents
mean ± SEM. n = 3.
(E and F) Flow cytometrical analyses of TNNT2 in
differentiation day 10 ESC lines. G&N, Gdnf, and
Nrtn.Gdnf- andNrtn-null ESC lines did not show any
statistically significant difference in cardiomyocyte
differentiation efficiency compared to WT. N.S., not
significant versus WT. Bar graph represents mean ±
SEM. n = 3. (F) Immunofluorescent images of TNNT2
in ESC lines at differentiation day 10. Scale bar,
100 mm.
(G) See also Figures S4–S6.whether the GFRA2 signaling pathway affecting cardiomyocyte
differentiation depends on RET, we generated Ret KO ESCs
lines. As expected from the phenotypes of KO mice, targeting
of Ret did not resulted in significantly impaired cardiomyocyte
differentiation (Figures 5A–5C, S4A, and S4B) (Airaksinen and
Saarma, 2002; Baloh et al., 2000; Paratcha and Ledda, 2008;
Schuchardt et al., 1994). This observation is also supported by
the fact that RET was not expressed in the heart fields (Fig-
ure S5A). In addition, the KO lines of Nrtn, Gdnf, and Nrtn/Gdnf
also did not show a significant defect (Figures 5E–5G, S5B,
and S5C) (Golden et al., 1999; Heuckeroth et al., 1999; Sa´nchez
et al., 1996). Collectively, these results indicate that cardiac
differentiation signaling via GFRA2 is independent of the co-re-
ceptor RET tyrosine kinase.
Previous studies have reported that the direct interaction be-
tween Neural Cell Adhesion Molecule (NCAM1) and GFRA1 me-
diates an alternative GFRA1 signaling pathway via FAK/FYN1032 Cell Reports 16, 1026–1038, July 26, 2016operating in the absence of any secreted
ligands and RET (Paratcha and Ledda,
2008; Paratcha et al., 2003; Sjo¨strand
et al., 2007). Although NCAM1 was not
expressed in the heart field (Figure S5A),
we cannot exclude the possibility that
another cell adhesion molecule mediates
a similar signal pathway. To confirm
whether a similar pathway is responsible
for the cardiac signaling of GFRA2, weinvestigated the phosphorylation of FAK, FYN, and its down-
stream ERK1/2 in Gfra1/2 DKO ESCs during cardiomyocyte dif-
ferentiation (Figure S6). Western blot analyses demonstrated
that FAK phosphorylation was slightly but significantly elevated
in Gfra1/2 DKO ESCs, whereas FYN and ERK1/2 phosphoryla-
tion were unaffected (Figure S6A). Since the NCAM1/GFRA1
signal pathway first activates FYN and phosphorylated-FYN ac-
tivates FAK (Paratcha et al., 2003), it is unlikely that a signal
similar to the NCAM1/GFRA1 signal mediated by a cell adhesion
molecule is operating. Thus, it suggests that FAK phosphoryla-
tion in Gfra1/2 DKO ESCs becomes elevated by an unknown
mechanism. We further tested whether the attenuation of
elevated FAK could rescue the phenotype of Gfra1/2 DKO
ESCs, since it has been previously reported that activated
FAK signaling impaired cardiomyocyte differentiation (Hakuno
et al., 2005). We administered the FAK inhibitor PF-573228 to
Gfra1/2 DKO ESCs during their differentiation. However, the
AB
C
Figure 6. Gfra1/2 Play Important Roles for the
Heart Development In Vivo
(A) Genotype of the Gfra1/2 DKO mouse embryos
generated by the direct injection of Gfra1-targeted
sgRNA, Gfra2-targeted sgRNA, and Cas9mRNA into
zygotes.
(B) WISH analyses of differentiated cardiomyocyte
marker Nppa in Gfra1/2 DKO and WT littermate em-
bryos at E8.5.Nppa expressions disappeared in DKO
embryos (red arrows). Scale bar, 250 mm.
(C) H&E staining for the hearts of Gfra1/2 DKO E17.5
embryos. The compaction layers of myocytes were
thin, and the alignments of cardiomyocytes were
impaired inGfra1/2DKO embryos as compared to the
control hearts (mCherry sgRNA and Cas9 mRNA
transduced embryos) and Gfra1/2 compound hetero-
zygote mutant. Gfra1 null resulted in kidney agenesis
as previously described (black arrowheads, No),
whereas the well-developed kidney was observed in
the heterozygotes andWT (black arrows, +) (Enomoto
et al., 1998). Themutation of each embryo induced by
CRISPR/Cas9 is shown in Figure S7B.
IVS, intraventricular septum; RV, right ventricle; LV,
left ventricle. Scale bar, 500 mm in whole-heart im-
ages and 100 mm in higher magnification. See also
Figure S7.efficiency of cardiomyocyte differentiation showed no improve-
ment even though FAK phosphorylation was kept within
physiological levels (Figures S6B and S6C). Therefore, the upre-
gulation of FAK signaling was not primarily responsible for
the defect of Gfra1/2 DKO ESCs. This signaling pathway oper-
ating via GFRA2 during cardiomyogenesis must activate effec-
tors of an alternative and critical circuit for cardiomyocyte
differentiation.
Gfra1/2Are Required for Ventricular Compaction In Vivo
To exclude the possibility that the phenotype observed inGfra1/2
DKOESCs is an in vitro phenomenon,wegeneratedGfra1/2DKO
mouse embryos by the direct transduction of (sgRNAs) forGfra1/
2 and Cas9 mRNA into zygotes (Figures 6A–6C and S7A–S7D)
(Wang et al., 2013). At first, we assayed the embryos at E8.5Cejust after heart tube formation, since embry-
onic defects or lethality would preclude
the analysis of later stage embryos. Em-
bryos containing multiples of three base
insertions/deletions inside the exon were
discarded from the analysis because the
presence of functional protein produc-
tion could not be refuted (Figure 6A). We
examined cardiomyocyte differentiation of
Gfra1/2 DKO embryos by WISH using a
marker of differentiated cardiomyocytes,
Nppa (also known as ANF) (Bruneau et al.,
2001; Christoffels et al., 2000). As expected
from our ESC experiments, Gfra1/2 DKO
embryos exhibited a significant reduction
of Nppa (Figure 6B), suggesting the cardio-
myocyte differentiation process was signifi-cantly affected. As expected from the data of Gfra2 KO ESCs
(Figure 5D), Gfra2 single-KO embryos showed significant but
transiently elevated Gfra1 expression by E8.5 in the heart field
(Figure S7A). However, despite the fact that cardiomyocyte
differentiation was impaired, the macro- and micro-anatomical
morphology of the formed heart tube appeared unaffected in
any DKO embryos (Figures 6B and S7B). This suggests that
the reduction of Nppa in Gfra1/2 DKO embryos simply reflected
a delay of cardiomyocyte differentiation. To clarify this, we
analyzed the Gfra1/2 DKO embryos at E17.5 (Figures 6C,
S7C, and S7D). Surprisingly, DKO embryos had the capacity
to develop up to this stage without edema, and developed
hearts were also observed (Figure 6C). This indicates that suffi-
cient cardiomyocyte differentiation occurred in DKO embryos
to support the fetal circulation. Further histological examinationll Reports 16, 1026–1038, July 26, 2016 1033
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Figure 7. Impaired NOTCH Signaling in Gfra1/2 DKO Embryos Is Responsible for Noncompaction Cardiomyopathy
(A) The unaltered structure of sarcomeres and mitochondria in the hearts of Gfra1/2 DKO embryos. The data represent biological triplicates. Scale bar, 500 nm.
(B) Downregulation of NOTCH1, BMP10, and ERBB4 in E9.5 DKO hearts (green). The data represent biological triplicates. Blue, DAPI; LV, left ventricle; RV, right
ventricle.
(C) Schematic model of the in vivo function of non-canonical Gfra1/2 signal pathway.
(D) Amodel of the expression pattern of GFRA2 and other surfacemarkers during differentiation of mouse and human pluripotent stem cells. At an earlier stage of
differentiation, GFRA2+/KDRlow+/PDGFRA+marks multipotent cardiovascular progenitors, whereas GFRA2+/KDR/PDGFRA+marks cardiac precursors that are
committed to cardiomyocytes fate at the later phase.
See also Figure S7.unexpectedly revealed thatGfra1/2DKOhearts at E17.5 suffered
from noncompaction cardiomyopathy (Figures 6C and S7D).
Excessively prominent trabeculations and deep intra-trabecular
recesses, which are characteristic features of noncompaction
cardiomyopathy, were apparent, but no other congenital heart
disease in DKO embryos was observed. However, the structure
of sarcomeres and mitochondria were not altered (Figures 7A
and S7C), suggesting that noncompaction was not caused by
the abnormality of sarcomeres and mitochondria (Towbin et al.,
2015). The absence ofGfra1/2 and Nrtn at the sites of trabecula-
tion and compaction suggests that RET-dependent and -inde-
pendentGFRA1/2 signal pathways do not directly or locally regu-
late trabeculation and compaction (Figures S7A, S7E, and S7F).
Importantly, we found that NOTCH1 in total protein and its down-
stream molecules BMP10 and ERBB4 were missing in DKO
hearts at E9.5 (Figure 7B). NOTCH signaling is essential for prolif-
eration and differentiation of ventricular cardiomyocytes through
which proper trabeculated and compactedmyocardial layers are1034 Cell Reports 16, 1026–1038, July 26, 2016formed, and mutants with NOTCH signaling defects exhibit a
noncompaction phenotype (de la Pompa and Epstein, 2012;
Grego-Bessa et al., 2007; Luxa´n et al., 2013; Zhang et al.,
2013). Thus, the ventricular noncompaction observed in DKO
embryos likely resulted from altered NOTCH signaling (Figures
7B and 7C).
Taken together, these results suggest that GFRA1/2 plays
an important function in normal mammalian heart development,
especially for ventricular wall compaction, but an unknown
mechanism could compensate for cardiomyocyte differentiation
due to the lack of GFRA1/2 in vivo. Thus, taken together, our data
reveal a non-canonical signal cascade via GFRA1/2 is indispens-
able for heart development in vivo.
DISCUSSION
Here, we report a surface marker, GFRA2, that is specific for
CPs in mouse and human. We show that the expression of
Gfra2 is initiated among both FHF and SHF CPs in vivo and
in vitro just before the initiation of spontaneous beating of cardi-
omyocytes.Gfra2 is downregulated after CPs terminally differen-
tiate to cardiomyocytes. The use of an antibody specific for
GFRA2 protein made it possible for us to harvest human and
mouse CPs derived from pluripotent stem cells. Physiologically,
Gfra2 plays an important role in heart development in vitro aswell
as in vivo, but, in the absence of Gfra2, ectopic activation of
Gfra1 can functionally compensate for its loss. Of note, our
data suggest that an alternative non-canonical signaling
cascade transmits GFRA1/2 activation to CP function, and that
this is distinct from the canonical signaling pathway dependent
on RET.
In differentiating ESCs, it is known that KDRlow+/PDGFRA+ or
KDRlow+/KITneg cells constitute multipotent CPs which give rise
to cardiomyocytes, smooth muscle cells, and endothelial cells,
based on previously reported clonal tracing experiments (Bondue
et al., 2011; Kattman et al., 2006, 2011; Yang et al., 2008). How-
ever, it remains an open question as to whether all of these cells
or only a proportion of these cells are CPs. In this study, we found
that almost all mouse KDRlow+/PDGFRA+ express GFRA2 (Fig-
ure 3). However, the situation is likely somewhat different in
human. The proportion of hGFRA2-expressing cells among
hKDRlow+/hPDGFRA+population ismuch lower (Figure4F).Asex-
pected, hKDRlow+/hPDGFRA+ cells are negative for KIT (Yang
etal., 2008).Ofnote,mostGFRA2-negativehKDRlow+/hPDGFRA+
cells failed to differentiate to cardiac cells (Figure S3E), which
strongly supports the specificity of hGFRA2 for human CPs.
Thus, inhumans, theadditional usageof hGFRA2 labeling is supe-
rior to the previously proposed protocols to isolate multipotent
CPs with high purity. Furthermore, the use of GFRA2 labeling
in addition to KDR and PDGFRA will enrich for more mature uni-
potent CPs which cannot be isolated with previous protocols
dependent on KDR expression. It is interesting that these unipo-
tent late-stage GFRA2+ CPs represent not only the FHF, repre-
sented by HCN4/TBX5 and already known as unipotent, but
also the SHF identified through expression of ISL1, because the
SHF CPs are generally thought as multipotent (Figures 2G, 4E,
S2D, and S2E) (Devine et al., 2014; Evans et al., 2010; Kelly and
Evans, 2010; Kokkinopoulos et al., 2015; Lescroart et al., 2014;
Spa¨ter et al., 2013). This evidence indicates that the late-stage
expression of GFRA2 excludes the multipotent SHF but includes
the already committed but not fully differentiated SHF lineage.
Thus, here we propose a strategy to isolate stage-specific
human and mouse CPs with GFRA2, PDGFRA, and KDR (Fig-
ure 7D). GFRA2+/KDRlow+/PDGFRA+ triple-positive CPs would
be multipotent cardiovascular progenitors. As CPs begin to
commit but not yet terminally differentiate to cardiomyocytes,
they lose KDR expression so that a GFRA2+/KDRneg/PDGFRA+
double-positive population represents a cardiomyocyte precur-
sor at a later stage.
We found that Gfra1/2 DKO mouse ESCs showed a severe
impairment of cardiomyocyte differentiation. Our data reveal
that GFRA2 plays a pivotal role in cardiomyocyte differentiation
in vitro that can be compensated by upregulation of GFRA1. Ex-
amples of an ectopic upregulation of an evolutionally duplicated
paralogous gene to compensate for loss of a gene have been
described (Barbaric et al., 2007). An evolutionally close relation-shipbetweenGfra1andGfra2suggests that apreservedcommon
enhancer drivesGfra1 ifGfra2 is not expressed in CPs, whereas a
high level of Gfra2 primarily suppresses Gfra1 (Barbaric et al.,
2007; Ha¨tinen et al., 2007). However, the phenotype of KO of
the known ligands for GFRA1 and 2, Gdnf and Nrtn, or KO of its
co-receptor Ret did not show any defect of cardiomyocyte differ-
entiation (Figures 5, S4, andS5). Interestingly, we observed a ten-
dency of a slightly reduced yield of cardiomyocytes in singleKOof
Gfra1,Gfra2, andRet, although not to a statistically significant de-
gree (Figure 5B). Given the evidence that previously reported KO
mice of each gene also did not show any heart defect (Enomoto
et al., 1998; Heuckeroth et al., 1999; Rossi et al., 1999; Sa´nchez
et al., 1996), the role of classic RET-dependent GFRA1/2 signals
are unlikely to be vital for heart development. In addition, whereas
an alternative GFRA1 signal pathway via NCAM1/FYN/FAK is
known (Paratcha et al., 2003; Sjo¨strand et al., 2007), our data
showed that NCAM1, FYN, and FAK were not involved in the car-
diac differentiation defect in the Gfra1/2 DKO (Figure S6). Thus,
the pathway by which GFRA2 modulates heart development is
likely to be distinct from previously established pathways. To
uncover the nature of this alternative non-canonical signaling
pathway acting via GFRA1/2, further investigation is required, to
identify molecules interacting directly with GFRA2 in the context
of cardiac differentiation.
In contrast to the in vitro phenotype, the loss-of-function of
Gfra1/2 showed a different phenotype in vivo. In E8.5 DKO em-
bryos, Nppa expression disappeared, which is likely consistent
with the impaired in vitro cardiomyocyte differentiation of DKO
ESCs. However, viable E17.5 DKO embryos possessing a devel-
oped heart were observed, indicating that cardiomyocyte differ-
entiation itself occurred to form a functional fetal heart in vivo.
Indeed, although missing Nppa, the heart tube of E8.5 DKO em-
bryos seemed morphologically normal (Figures 6B and S7B).
This evidence is inconsistentwith the in vitrophenotypeof ablated
cardiomyocyte differentiation in DKOESCs. Thus, the disappear-
ance of Nppa in E8.5 DKO embryos might simply represent the
delay of cardiomyocyte differentiation or anomalous sequential
events inside the cardiomyocytes in DKO embryos. We propose
that an unknown compensatory mechanism functions in vivo
to circumvent the lack of GFRA1/2 to promote cardiomyocyte
differentiation. Although the differentiation protocol for ESCs
used in this study provides a strong drive toward cardiomyocytes
with a defined set of growth factors (Kattman et al., 2011; Wam-
stad et al., 2012), these conditions are probably insufficient to
perfectly mimic the in vivo environment for cardiomyocyte
differentiation.
E17.5 DKO embryos showed noncompaction cardiomyopathy
without other congenital heart diseases (Towbin et al., 2015;
Zhang et al., 2013). We speculate that these DKO mice would
not survive after birth because of the extremely thin compact
layer of the ventricular wall. However, absence of edema in
E17.5 DKO embryos suggests that the contractile apparatus in
DKO cardiomyocytes at least developed sufficiently to support
the fetal circulation. Unfortunately, germline deletion of Gfra1
does not allow neonates to survive due to kidney agenesis (Fig-
ure 6C) (Enomoto et al., 1998; Sa´nchez et al., 1996). Thus, to
confirm the perinatal prognosis, a conditional knockout will be
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Importantly, we found that NOTCH1 and its downstream
targets, BMP10 and ERBB4, were significantly downregulated
in DKO embryos, and that this might be responsible for the non-
compaction defect (Figures 7B and 7C) (Grego-Bessa et al.,
2007; Luxa´n et al., 2013; Zhang et al., 2013). Given the lack of
Nppa expression in NOTCH signal mutants (Luxa´n et al., 2013),
it is concluded that the altered NOTCH signal in the endocardium
promotes the downregulation ofNppa in DKO embryos. Surpris-
ingly, Gfra2 is expressed by CPs, but not at the sites of trabecu-
lation or compaction (Figures 1, S1, S7E, and S7F). Thus, the
defect within the endocardium is cell autonomously induced by
the loss of Gfra1/2 in multipotent CPs and is likely primarily
required for ventricular noncompaction, although we cannot
exclude a possibility that additional defects within the myocar-
dium of DKO embryos may also contribute to this phenotype
(Figure 7C).
Taken together, an alternative signaling pathway via GFRA1/2
is indispensable for proper heart development, although the
mechanism underlying the signaling pathway of cardiac differen-
tiation mediated by GFRA2 has yet to be elucidated. Future
work, involving the clarification of the mechanistic details of
this signaling pathway should provide deeper insight into cardi-
omyocyte differentiation, the biology of CPs, normal trabecula-
tion, and compaction of ventricular myocytes.
EXPERIMENTAL PROCEDURES
The details are given in the Supplemental Experimental Procedures.
Animals
All animal procedures in this project were carried out under the project licenses
70/7254 and 80/2452 and 27-028-001 approved by the Home Office accord-
ing to the Animals (Scientific Procedures) Act 1986 in the UK and Osaka
University Animal Ethical Committee in Japan, respectively.
Cell Culture and Differentiation
Cardiomyocyte induction for mouse E14tg2a ESCs (Magin et al., 1992; Smith
and Hooper, 1987) was performed according to standard protocols as previ-
ously described (Kattman et al., 2011). Cardiomyocyte induction from human
HUES7 ESCs or iPSCs was undertaken as previously described (Burridge
et al., 2011). Human ESCs were used under the license of the UK Steering
Committee (reference number; SCSC13-25). Human iPSCs (iPS-HS1M)
were originally established by D.M. using human dermal fibroblasts (HDFs)
from a healthy donor under informed consent (Health Research Authority
approval 13/LO/0224), for a study to be described elsewhere (D.M., T. McKay,
L.D., and A.T., unpublished data).
CRISPR/Cas9-Mediated Genome Editing
The CRISPR/Cas9-mediated genome editing for mouse ESCs and embryos
was performed as previously described (Hashimoto and Takemoto, 2015;
Wang et al., 2013).
Flow Cytometry/FACS
Cells were sorted as previously described using FACS ARIA II or analyzed by
LSR Fortessa II or FACSConto II (BD Biosciences) with FACSDiva 7.0 software
(Kokkinopoulos et al., 2015).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and two movies and can be found with this article online at
http://dx.doi.org/10.1016/j.celrep.2016.06.050.1036 Cell Reports 16, 1026–1038, July 26, 2016AUTHOR CONTRIBUTIONS
K.Y. planned this project, and H.I. and K.Y. performed the majority of the ex-
periments. K.Y. and H.I. wrote the manuscript. R.S., I.K., S.N., A-K.H., M.S.,
P.R., and K.O. contributed to mouse ESC experiments. A.P., D.M., S.H.,
L.D., A.T., and K.O. contributed to human ESCs and human iPSCs experi-
ments. M.H. and H.S. contributed to CRISPR/Cas9-mediated direct genome
editing. O.Y. and Y. Sakata contributed to electron microscopy observations.
S.K., A-K.H., Y. Sawa, K.O., and K.S. contributed to the discussion of the
results.
ACKNOWLEDGMENTS
This work was supported by the MRC New Investigator Research grant
G0900105 and MRC Research grant MR/J007625/1 to K.Y., Japan Heart
Foundation/Bayer Yakuhin Research Grant Abroad and JSPS (Japan Society
for the Promotion of Science) Postdoctoral Fellowship for Research Abroad to
H.I., and NIHR-funded Barts CVBRU. We thank Marika Charalambous and
Kinya Otsu for helpful discussions; Hiroshi Hamada, Jinsuke Nishino, Denise
Duboule, John Cobb, and Tristan McKay for sharing materials; and Timothy
Mohun, Sophie Wood, and Sarah Johnson for help with microinjection of
CRISPR/Cas9.
Received: February 11, 2016
Revised: May 22, 2016
Accepted: June 10, 2016
Published: July 7, 2016
REFERENCES
Airaksinen, M.S., and Saarma, M. (2002). The GDNF family: signalling, biolog-
ical functions and therapeutic value. Nat. Rev. Neurosci. 3, 383–394.
Baloh, R.H., Tansey, M.G., Johnson, E.M., Jr., and Milbrandt, J. (2000).
Functional mapping of receptor specificity domains of glial cell line-derived
neurotrophic factor (GDNF) family ligands and production of GFRalpha1
RET-specific agonists. J. Biol. Chem. 275, 3412–3420.
Barbaric, I., Miller, G., and Dear, T.N. (2007). Appearances can be deceiving:
phenotypes of knockout mice. Brief. Funct. Genomics Proteomics 6, 91–103.
Bondue, A., Ta¨nnler, S., Chiapparo, G., Chabab, S., Ramialison, M., Paulissen,
C., Beck, B., Harvey, R., and Blanpain, C. (2011). Defining the earliest step of
cardiovascular progenitor specification during embryonic stem cell differenti-
ation. J. Cell Biol. 192, 751–765.
Brouilette, S., Kuersten, S., Mein, C., Bozek, M., Terry, A., Dias, K.R., Bhaw-
Rosun, L., Shintani, Y., Coppen, S., Ikebe, C., et al. (2012). A simple and novel
method for RNA-seq library preparation of single cell cDNA analysis by hyper-
active Tn5 transposase. Dev. Dyn. 241, 1584–1590.
Bruneau, B.G., Nemer, G., Schmitt, J.P., Charron, F., Robitaille, L., Caron, S.,
Conner, D.A., Gessler, M., Nemer, M., Seidman, C.E., and Seidman, J.G.
(2001). Amurinemodel of Holt-Oram syndrome defines roles of the T-box tran-
scription factor Tbx5 in cardiogenesis and disease. Cell 106, 709–721.
Burridge, P.W., Thompson, S., Millrod, M.A., Weinberg, S., Yuan, X., Peters,
A., Mahairaki, V., Koliatsos, V.E., Tung, L., and Zambidis, E.T. (2011). A univer-
sal system for highly efficient cardiac differentiation of human induced plurip-
otent stem cells that eliminates interline variability. PLoS ONE 6, e18293.
Cai, C.L., Liang, X., Shi, Y., Chu, P.H., Pfaff, S.L., Chen, J., and Evans, S.
(2003). Isl1 identifies a cardiac progenitor population that proliferates prior to
differentiation and contributes a majority of cells to the heart. Dev. Cell 5,
877–889.
Christoffels, V.M., Habets, P.E., Franco, D., Campione, M., de Jong, F.,
Lamers, W.H., Bao, Z.Z., Palmer, S., Biben, C., Harvey, R.P., and Moorman,
A.F. (2000). Chamber formation and morphogenesis in the developing
mammalian heart. Dev. Biol. 223, 266–278.
Cong, L., Ran, F.A., Cox, D., Lin, S., Barretto, R., Habib, N., Hsu, P.D., Wu, X.,
Jiang, W., Marraffini, L.A., and Zhang, F. (2013). Multiplex genome engineering
using CRISPR/Cas systems. Science 339, 819–823.
de la Pompa, J.L., and Epstein, J.A. (2012). Coordinating tissue interac-
tions: Notch signaling in cardiac development and disease. Dev. Cell 22,
244–254.
Devine, W.P., Wythe, J.D., George, M., Koshiba-Takeuchi, K., and Bruneau,
B.G. (2014). Early patterning and specification of cardiac progenitors in gastru-
lating mesoderm. eLife 3, 3.
Downs, K.M., and Davies, T. (1993). Staging of gastrulatingmouse embryos by
morphological landmarks in the dissecting microscope. Development 118,
1255–1266.
Enomoto, H., Araki, T., Jackman, A., Heuckeroth, R.O., Snider, W.D., Johnson,
E.M., Jr., and Milbrandt, J. (1998). GFR alpha1-deficient mice have deficits in
the enteric nervous system and kidneys. Neuron 21, 317–324.
Evans, S.M., Yelon, D., Conlon, F.L., and Kirby, M.L. (2010). Myocardial line-
age development. Circ. Res. 107, 1428–1444.
Fu, Y., Foden, J.A., Khayter, C., Maeder, M.L., Reyon, D., Joung, J.K., and
Sander, J.D. (2013). High-frequency off-target mutagenesis induced by
CRISPR-Cas nucleases in human cells. Nat. Biotechnol. 31, 822–826.
Golden, J.P., DeMaro, J.A., Osborne, P.A., Milbrandt, J., and Johnson, E.M.,
Jr. (1999). Expression of neurturin, GDNF, and GDNF family-receptor mRNA
in the developing and mature mouse. Exp. Neurol. 158, 504–528.
Grego-Bessa, J., Luna-Zurita, L., del Monte, G., Bolo´s, V., Melgar, P., Ara-
ndilla, A., Garratt, A.N., Zang, H., Mukouyama, Y.S., Chen, H., et al. (2007).
Notch signaling is essential for ventricular chamber development. Dev. Cell
12, 415–429.
Hakuno, D., Takahashi, T., Lammerding, J., and Lee, R.T. (2005). Focal adhe-
sion kinase signaling regulates cardiogenesis of embryonic stem cells. J. Biol.
Chem. 280, 39534–39544.
Hashimoto, M., and Takemoto, T. (2015). Electroporation enables the efficient
mRNA delivery into the mouse zygotes and facilitates CRISPR/Cas9-based
genome editing. Sci. Rep. 5, 11315.
Ha¨tinen, T., Holm, L., and Airaksinen, M.S. (2007). Loss of neurturin in frog–
comparative genomics study of GDNF family ligand-receptor pairs. Mol.
Cell. Neurosci. 34, 155–167.
Heuckeroth, R.O., Enomoto, H., Grider, J.R., Golden, J.P., Hanke, J.A., Jack-
man, A., Molliver, D.C., Bardgett, M.E., Snider, W.D., Johnson, E.M., Jr., and
Milbrandt, J. (1999). Gene targeting reveals a critical role for neurturin in the
development and maintenance of enteric, sensory, and parasympathetic neu-
rons. Neuron 22, 253–263.
Hidaka, K., Shirai, M., Lee, J.K., Wakayama, T., Kodama, I., Schneider, M.D.,
and Morisaki, T. (2010). The cellular prion protein identifies bipotential cardio-
myogenic progenitors. Circ. Res. 106, 111–119.
Hiltunen, J.O., Laurikainen, A., Airaksinen, M.S., and Saarma, M. (2000). GDNF
family receptors in the embryonic and postnatal rat heart and reduced cholin-
ergic innervation in mice hearts lacking ret or GFRalpha2. Dev. Dyn. 219,
28–39.
Kataoka, H., Takakura, N., Nishikawa, S., Tsuchida, K., Kodama, H., Kunisada,
T., Risau, W., Kita, T., and Nishikawa, S.I. (1997). Expressions of PDGF re-
ceptor alpha, c-Kit and Flk1 genes clustering in mouse chromosome 5
define distinct subsets of nascent mesodermal cells. Dev. Growth Differ. 39,
729–740.
Kathiriya, I.S., Nora, E.P., and Bruneau, B.G. (2015). Investigating the tran-
scriptional control of cardiovascular development. Circ. Res. 116, 700–714.
Kattman, S.J., Huber, T.L., and Keller, G.M. (2006). Multipotent flk-1+ cardio-
vascular progenitor cells give rise to the cardiomyocyte, endothelial, and
vascular smooth muscle lineages. Dev. Cell 11, 723–732.
Kattman, S.J., Witty, A.D., Gagliardi, M., Dubois, N.C., Niapour, M., Hotta, A.,
Ellis, J., and Keller, G. (2011). Stage-specific optimization of activin/nodal and
BMP signaling promotes cardiac differentiation of mouse and human pluripo-
tent stem cell lines. Cell Stem Cell 8, 228–240.
Kelly, R.G., and Evans, S.M. (2010). The Second Heart Field, First Edition,
Volume 1 (Academic Press, Elsevier).
Kinder, S.J., Tsang, T.E., Quinlan, G.A., Hadjantonakis, A.K., Nagy, A., and
Tam, P.P. (1999). The orderly allocation of mesodermal cells to the extraem-bryonic structures and the anteroposterior axis during gastrulation of the
mouse embryo. Development 126, 4691–4701.
Kokkinopoulos, I., Ishida, H., Saba, R., Ruchaya, P., Cabrera, C., Struebig, M.,
Barnes, M., Terry, A., Kaneko, M., Shintani, Y., et al. (2015). Single-cell expres-
sion profiling reveals a dynamic state of cardiac precursor cells in the early
mouse embryo. PLoS ONE 10, e0140831.
Lescroart, F., Chabab, S., Lin, X., Rulands, S., Paulissen, C., Rodolosse, A.,
Auer, H., Achouri, Y., Dubois, C., Bondue, A., et al. (2014). Early lineage restric-
tion in temporally distinct populations of Mesp1 progenitors during mamma-
lian heart development. Nat. Cell Biol. 16, 829–840.
Liang, X.,Wang, G., Lin, L., Lowe, J., Zhang, Q., Bu, L., Chen, Y., Chen, J., Sun,
Y., and Evans, S.M. (2013). HCN4 dynamically marks the first heart field and
conduction system precursors. Circ. Res. 113, 399–407.
Luxa´n, G., Casanova, J.C., Martı´nez-Poveda, B., Prados, B., D’Amato, G.,
MacGrogan, D., Gonzalez-Rajal, A., Dobarro, D., Torroja, C., Martinez, F.,
et al. (2013). Mutations in the NOTCH pathway regulator MIB1 cause left
ventricular noncompaction cardiomyopathy. Nat. Med. 19, 193–201.
Magin, T.M., McWhir, J., and Melton, D.W. (1992). A new mouse embryonic
stem cell line with good germ line contribution and gene targeting frequency.
Nucleic Acids Res. 20, 3795–3796.
McGrath, K.E., Koniski, A.D., Maltby, K.M., McGann, J.K., and Palis, J. (1999).
Embryonic expression and function of the chemokine SDF-1 and its receptor,
CXCR4. Dev. Biol. 213, 442–456.
Nelson, T.J., Faustino, R.S., Chiriac, A., Crespo-Diaz, R., Behfar, A., and
Terzic, A. (2008). CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage
from embryonic stem cells. Stem Cells 26, 1464–1473.
Paige, S.L., Plonowska, K., Xu, A., and Wu, S.M. (2015). Molecular regulation
of cardiomyocyte differentiation. Circ. Res. 116, 341–353.
Paratcha, G., and Ledda, F. (2008). GDNF andGFRalpha: a versatile molecular
complex for developing neurons. Trends Neurosci. 31, 384–391.
Paratcha, G., Ledda, F., and Iba´n˜ez, C.F. (2003). The neural cell adhesion
molecule NCAM is an alternative signaling receptor for GDNF family ligands.
Cell 113, 867–879.
Rana, M.S., Christoffels, V.M., and Moorman, A.F. (2013). A molecular and
genetic outline of cardiac morphogenesis. Acta Physiol. (Oxf.) 207, 588–615.
Rossi, J., Luukko, K., Poteryaev, D., Laurikainen, A., Sun, Y.F., Laakso, T.,
Eerika¨inen, S., Tuominen, R., Lakso, M., Rauvala, H., et al. (1999). Retarded
growth and deficits in the enteric and parasympathetic nervous system
in mice lacking GFR alpha2, a functional neurturin receptor. Neuron 22,
243–252.
Rossi, J., Herzig, K.H., Vo˜ikar, V., Hiltunen, P.H., Segerstra˚le, M., and Airaksi-
nen, M.S. (2003). Alimentary tract innervation deficits and dysfunction in mice
lacking GDNF family receptor alpha2. J. Clin. Invest. 112, 707–716.
Sa´nchez, M.P., Silos-Santiago, I., Frise´n, J., He, B., Lira, S.A., and Barbacid,
M. (1996). Renal agenesis and the absence of enteric neurons in mice lacking
GDNF. Nature 382, 70–73.
Schuchardt, A., D’Agati, V., Larsson-Blomberg, L., Costantini, F., and Pachnis,
V. (1994). Defects in the kidney and enteric nervous system of mice lacking the
tyrosine kinase receptor Ret. Nature 367, 380–383.
Scott, R.P., and Ibanez, C.F. (2001). Determinants of ligand binding specificity
in the glial cell line-derived neurotrophic factor family receptor alpha S. J. Biol.
Chem. 276, 1450–1458.
Sjo¨strand, D., Carlsson, J., Paratcha, G., Persson, B., and Iba´n˜ez, C.F. (2007).
Disruption of the GDNF binding site in NCAM dissociates ligand binding and
homophilic cell adhesion. J. Biol. Chem. 282, 12734–12740.
Smith, A.G., and Hooper, M.L. (1987). Buffalo rat liver cells produce a diffusible
activity which inhibits the differentiation of murine embryonal carcinoma and
embryonic stem cells. Dev. Biol. 121, 1–9.
Spa¨ter, D., Abramczuk,M.K., Buac, K., Zangi, L., Stachel, M.W., Clarke, J., Sa-
hara, M., Ludwig, A., and Chien, K.R. (2013). A HCN4+ cardiomyogenic pro-
genitor derived from the first heart field and human pluripotent stem cells.
Nat. Cell Biol. 15, 1098–1106.Cell Reports 16, 1026–1038, July 26, 2016 1037
Stanley, E.G., Biben, C., Elefanty, A., Barnett, L., Koentgen, F., Robb, L., and
Harvey, R.P. (2002). Efficient Cre-mediated deletion in cardiac progenitor cells
conferred by a 3’UTR-ires-Cre allele of the homeobox geneNkx2-5. Int. J. Dev.
Biol. 46, 431–439.
Towbin, J.A., Lorts, A., and Jefferies, J.L. (2015). Left ventricular non-compac-
tion cardiomyopathy. Lancet 386, 813–825.
Wamstad, J.A., Alexander, J.M., Truty, R.M., Shrikumar, A., Li, F., Eilertson,
K.E., Ding, H., Wylie, J.N., Pico, A.R., Capra, J.A., et al. (2012). Dynamic and
coordinated epigenetic regulation of developmental transitions in the cardiac
lineage. Cell 151, 206–220.1038 Cell Reports 16, 1026–1038, July 26, 2016Wang, H., Yang, H., Shivalila, C.S., Dawlaty,M.M., Cheng, A.W., Zhang, F., and
Jaenisch, R. (2013). One-step generation ofmice carryingmutations inmultiple
genes by CRISPR/Cas-mediated genome engineering. Cell 153, 910–918.
Yang, L., Soonpaa, M.H., Adler, E.D., Roepke, T.K., Kattman, S.J., Kennedy,
M., Henckaerts, E., Bonham, K., Abbott, G.W., Linden, R.M., et al. (2008).
Human cardiovascular progenitor cells develop from a KDR+ embryonic-
stem-cell-derived population. Nature 453, 524–528.
Zhang, W., Chen, H., Qu, X., Chang, C.P., and Shou, W. (2013). Molecular
mechanism of ventricular trabeculation/compaction and the pathogenesis of
the left ventricular noncompaction cardiomyopathy (LVNC). Am. J. Med.
Genet. C. Semin. Med. Genet. 163C, 144–156.
